Isabella Hornick

6 days ago | healio.com | Isabella Hornick

Key takeaways:The ability to think strategically about how to safeguard ATS for future generations is one quality of an ATS leader. Individuals can start getting involved with ATS early through assemblies and committees. Preparing for his 2025 to 2026 term as American Thoracic Society president, Raed A. Dweik, MD, MBA, ATSF, plans to uphold the society’s premier status and make it a welcoming community for all people with an interest in respiratory disease.

1 week ago | healio.com | Isabella Hornick

Key takeaways: Only 33% of editors and editorial board members for these journals were women. There are four ways journals can improve representation. Women interested in these jobs can see if current editors would mentor them. The proportion of women editors and editorial board members for highly cited allergy journals was smaller than that of men in these positions, according to data published in The Journal of Allergy and Clinical Immunology: In Practice.

1 week ago | healio.com | Isabella Hornick

Key takeaways: The replicate, multicenter, randomized, double-blind, double-dummy, parallel group KALOS and LOGOS phase 3 trials achieved their primary endpoints. AstraZeneca will present full data at an upcoming meeting. Breztri Aerosphere, a triple inhaled therapy, met its primary endpoint of lung function improvement in adults and adolescents with uncontrolled asthma in two phase 3 trials, according to a press release from AstraZeneca.

1 week ago | healio.com | Isabella Hornick

Key takeaways: The Circul ring has the ability to measure blood oxygen level. Researchers found high area under the curve values with the Circul ring in determining OSA severity vs. polysomnography-derived measures. Across three obstructive sleep apnea severity levels, the Circul ring had “good diagnostic accuracy” using oxygen desaturation measures, according to results published inRespiratory Medicine.

1 week ago | healio.com | Isabella Hornick

Key takeaways: Smoking abstinence during weeks 9 to 12 was 30.3% with 12-week cytisinicline vs. 9.4% with placebo. Cytisinicline was well tolerated, with only 1.7% of adults discontinuing treatment because of an adverse event. More adults receiving 6- or 12-week cytisinicline vs. placebo achieved smoking abstinence in the last 4 weeks of treatment, according to results published inJAMA Internal Medicine.